Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6.
More than 750 million people are at risk of infection with foodborne liver flukes. Opisthorchis viverrini is considered among the most important of these parasites, due to its strong association with cholangiocarcinoma (CCA). O. viverrini infection results in a chronic inflammatory challenge to the host, which can lead to advanced, pathogen-specific disease sequelae including obstructive jaundice, hepatomegaly, cholecystitis, as well as CCA. However, before disease sequelae are apparent, important inflammatory changes to the liver can be detected early during O. viverrini infection. In a case-control study involving 328 men and women with O. viverrini infection, we determined the presence of advanced periductal fibrosis in asymptomatic, O. viverrini-infected individuals and then measured cytokine responses to O. viverrini excretory/secretory products (ES). In the 200 participants with advanced periductal fibrosis (cases), levels of interleukin-6 (IL-6) to O. viverrini ES were 8 times higher than levels of the 128 O. viverrini-infected individuals without advanced periductal fibrosis (controls). Moreover, elevated IL-6 to parasite ES was associated with increased risk of advanced periductal fibrosis by 63% in a model adjusted for sex and age. The risk of advanced periductal fibrosis was also found to increase with higher levels of IL-6: individuals in the third quartile of IL-6-ES production had a 127% higher risk of developing advanced periductal fibrosis than individuals in the first quartile of IL-6 production. O. viverrini-infected individuals with advanced periductal fibrosis showed other hepatobiliary abnormalities, including reduced gallbladder contractility and the presence of gallbladder sludge.


CONCLUSIONS
These data strongly implicate a role for parasite-specific IL-6 in the pathogenesis of advanced periductal fibrosis in opisthorchiasis, with possible links to other hepatobiliary abnormalities, including CCA.
Sripa
Banchob
B
Department of Pathology, Khon Kaen University School of Medicine, Khon Kaen, Thailand.
Mairiang
Eimorn
E
Thinkhamrop
Bandit
B
Laha
Thewarach
T
Kaewkes
Sasithorn
S
Sithithaworn
Paiboon
P
Tessana
Smarn
S
Loukas
Alex
A
Brindley
Paul J
PJ
Bethony
Jeffrey M
JM
D000328:Adult; D000818:Animals; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D005704:Gallbladder / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008099:Liver / Q000469:parasitology* / Q000473:pathology; D008103:Liver Cirrhosis / Q000097:blood* / Q000453:epidemiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009889:Opisthorchiasis / Q000097:blood* / Q000150:complications / Q000473:pathology; D009891:Opisthorchis / Q000472:pathogenicity*; D012307:Risk Factors
D015415:Biomarkers; D015850:Interleukin-6
Arzneimittelforschung. 1984;34(9B):1167-9
6542384
Parasite Immunol. 2000 Mar;22(3):139-45
10672195
Cell. 2006 Feb 24;124(4):823-35
16497591
Arzneimittelforschung. 1984;34(9B):1175-7
6542387
Int J Clin Pharmacol Ther. 1997 Sep;35(9):385-8
9314092
Hepatology. 1991 Feb;13(2):267-76
1995437
J Gastroenterol Hepatol. 1992 Jan-Feb;7(1):17-21
1311966
Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):431-3
17059338
Int J Cancer. 2006 Jun 15;118(12):3030-44
16404738
Am J Trop Med Hyg. 1996 Sep;55(3):295-301
8842118
Nat Clin Pract Rheumatol. 2006 Nov;2(11):619-26
17075601
Chronic Illn. 2008 Mar;4(1):65-79
18322031
Acta Trop. 2003 Nov;88(3):221-7
14611876
J Invest Dermatol. 2007 Jan;127(1):98-105
17024100
Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):194-7
8337727
Int J Parasitol. 2009 Jun;39(7):825-35
19168069
Carcinogenesis. 1998 Mar;19(3):485-91
9525284
Am J Physiol Gastrointest Liver Physiol. 2004 Sep;287(3):G497-502
15331349
J Immunol. 1991 Feb 15;146(4):1271-6
1846896
Parasitology. 2004 Oct;129(Pt 4):455-64
15521634
Parasite Immunol. 2007 Mar;29(3):159-67
17266743
PLoS Med. 2007 Jul;4(7):e201
17622191
Acta Trop. 2003 Nov;88(3):209-20
14611875
Panminerva Med. 1996 Dec;38(4):207-10
9063027
J Pathol. 2008 Jan;214(2):199-210
18161745
Trends Mol Med. 2008 Mar;14(3):109-19
18261959
Hepatology. 2008 Jun;47(6):2127-33
18446789
Abdom Imaging. 2008 Mar-Apr;33(2):157-65
17934771
Am J Pathol. 1994 Nov;145(5):1237-45
7977654
Acta Trop. 2003 Nov;88(3):187-94
14611873
J Gastroenterol. 1997 Apr;32(2):211-5
9085170
J Hepatol. 2006 Dec;45(6):856-67
17030071
Parasite Immunol. 1986 Sep;8(5):455-66
3490651
Am J Gastroenterol. 1991 Dec;86(12):1804-8
1962626
J Clin Invest. 2007 Mar;117(3):524-9
17332879
Am J Trop Med Hyg. 1978 Jul;27(4):787-94
686245
Acta Trop. 2002 Jul;83(1):29-36
12062790
Lancet. 2005 Apr 30-May 6;365(9470):1561-9
15866310
Immunol Rev. 2004 Oct;201:89-116
15361235
IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241
7715068
Trop Med Int Health. 2004 May;9(5):588-94
15117303
Hepatology. 2008 Jul;48(1):308-21
18536057
Nature. 2004 Sep 23;431(7007):461-6
15329734
Biometrics. 1977 Mar;33(1):159-74
843571
Emerg Infect Dis. 2005 Oct;11(10):1507-14
16318688
J Clin Invest. 2008 Apr;118(4):1311-21
18382743